Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
ColciGel®
(colchicinum 4X) Tansdermal Gel
No information provided.
ColciGel® transdermal gel is indicated for prophylaxis and the treatment of acute gout flares.
ColciGel® gel is indicated for treatment of acute gout flares when used at the first sign of a flare.
ColciGel® is indicated for prophylaxis of gout flares.
Apply 1 – 4 pumps up to four times per day. 1 application = 1 pump (0.25ml) covers an area 4” in diameter.
Children under 16 years of age do not use unless directed by a physician.
ColciGel® is Colchicinum 4X in a transdermal gel base. The gel is viscous and opaque in appearance. ColciGel® is available in 15 mL sealed dispensing containers that produce 0.25 mL of gel per each manual depression of the plunger top (pump).
ColciGel® is Colchicinum 4X in a transdermal gel base. The gel is viscous and opaque in appearance.
ColciGel® is available in 2x15mL sealed dispensing containers that produce 0.25 mL of gel per each manual depression of the plunger top (pump).
2 x 15mL (1.01 fl oz) Bottles NDC 35781-0400-4
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]
DISPENSE IN ORIGINAL CONTAINER.
Manufactured for: Gensco Laboratories,LLC, Doral, FL 33122, 866-608-6284. Revised: May 2015
The most commonly reported adverse reaction in clinical trials for the prophylaxis and treatment of gout was mild skin irritation at the site of application.
ColciGel® (Colchicinum 4X) is a substrate of the efflux transporter P-glycoprotein (P-gp). Of the cytochrome P450 enzymes tested, CYP3A4 was mainly involved in the metabolism of colchicinum. If ORAL colchicine is administered with drugs that inhibit P-gp, most of which also inhibit CYP3A4, increased concentrations of colchicinum are likely. Fatal drug interactions have been reported. Topical application of ColciGel® has demonstrated insignificant systemic absorption in animal testing and confirmed in limited human pharmacokinetic evaluations and, therefore, poses a limited risk of clinically significant drug interactions. Physicians should, however, ensure that patients are suitable candidates for treatment with ColciGel® and remain alert for signs and symptoms of toxicities related to increased colchicinum exposure as a result of a drug interaction. Signs and symptoms of ColciGel® toxicity should be evaluated promptly and, if toxicity is suspected, ColciGel® should be discontinued immediately.
For External Use Only
No human or animal studies on the effect of ColciGel® (colchicinum 4X) in pregnancy have been conducted.
It is not known whether ColciGel® (colchicinum 4X) is excreted in breast milk.
Carcinogenicity studies of colchicinum have not been conducted. Due to the potential for colchicinum to produce aneuploid cells (cells with an unequal number of chromosomes), there is theoretically an increased risk of malignancy.
Colchicine was negative for mutagenicity in the bacterial reverse mutation assay. In a chromosomal aberration assay in cultured human white blood cells, colchicine treatment resulted in the formation of micronuclei. Since published studies demonstrated that colchicine induces aneuploidy from the process of mitotic nondisjunction without structural DNA changes, colchicine is not considered clastogenic, although micronuclei are formed.
No studies of colchicinum effects on fertility were conducted with ColciGel®. However, published nonclinical studies demonstrated that colchicine-induced disruption of microtubule formation affects meiosis and mitosis. Reproductive studies also reported abnormal sperm morphology and reduced sperm counts in males, and interference with sperm penetration, second meiotic division, and normal cleavage in females when exposed to colchicine. Colchicine administered to pregnant animals resulted in fetal death and teratogenicity. These effects were dose dependent, with the timing of exposure critical for the effects on embryofetal development. The nonclinical doses evaluated were generally higher than an equivalent human ORAL therapeutic dose, but safety margins for reproductive and developmental toxicity could not be determined. Case reports and epidemiology studies in human male subjects on colchicine therapy indicated that infertility from colchicine is rare. A case report indicated that azoospermia was reversed when therapy was stopped. Case reports and epidemiology studies in female subjects on colchicine therapy have not established a clear relationship between colchicinum use and female infertility. The use of colchicinum needs to be weighed against the potential risks.
No information provided.
Patients with severe renal or severe hepatic impairment should not be given ColciGel® in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors, except fosamprenavir). In these patients, life-threatening and fatal colchicine toxicity has been reported with ORAL colchicines taken in therapeutic doses.
The mechanism by which colchicinum exerts its beneficial effect in patients has not been fully elucidated; however, evidence suggests that colchicinum may interfere with the intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediates activation of interleukin-1alpha. Additionally, colchicine disrupts cytoskeletal functions through inhibition of alphatubulin polymerization into microtubules and consequently prevents the activation, degranulation, and migration of neutrophils thought to mediate some gout symptoms.
QNo information provided. Please refer to the WARNINGS AND PRECAUTIONS sections.
